Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback